Adtalem Global Education Inc. (ATGE) Stock Analysis
Adtalem has reinvented itself into America’s largest healthcare talent pipeline—compounding earnings with operating leverage and buybacks while the market still prices in an outdated regulatory discount.
Overview
Adtalem Global Education (ATGE) has completed a multi-year transformation from a diversified education operator into a focused “healthcare pure-play,” positioning itself as a systemically important supplier of U.S. healthcare labor. Its schools—Chamberlain, Walden, and the Medical & Veterinary portfolio—function as a scaled pipeline producing nurses, physicians, and veterinarians, making demand less tied to traditional higher-ed cyclicality and more tied to licensure-driven, inelastic healthcare needs. Operational execution is accelerating: Q1 FY2026 revenue rose 10.8% to $462.3M and adjusted EPS grew 35.7% to $1.75, supported by a ninth straight quarter of total enrollment growth (97,359 students) and expanding adjusted EBITDA margin to 24.2%. The Walden acquisition is now delivering real synergies and digital operating leverage, while leverage has been reduced to ~0.6x. Despite this momentum, ATGE trades at a meaningful valuation discount to peers (notably LOPE), largely due to lingering regulatory risk perceptions. With robust free cash flow and an active $150M buyback authorization, the setup is framed as GARP: structural growth plus disciplined capital return with potential multiple expansion if regulatory concerns continue to fade.